glucose, (beta-d)-isomer has been researched along with Symptom Cluster in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (37.50) | 18.7374 |
1990's | 3 (37.50) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Britti, D; Caputi, AP; Cuzzocrea, S; De Sarro, A; Di Paola, R; Dugo, L; Genovese, T; Rossi, A; Sautebin, L; Sciarra, G; Serraino, I | 1 |
Chouker, A; Hoelzl, A; Hummel, T; Kaufmann, I; Peter, K; Schliephake, F; Thiel, M | 1 |
Goris, RJ; Hendriks, T; Huyben, CM; Jansen, MJ; Tax, WJ; van der Meer, JW | 1 |
Cook, DN; Kotwal, GJ; Miller, CG | 1 |
Shahan, TA; Simpson, J; Sorenson, WG | 1 |
Chi, EY; Fauci, AS; Harley, JB; Henderson, WR | 1 |
Leirisalo-Repo, M; Repo, H; Savilahti, E | 1 |
Basford, RE; Kaplan, SS; Kuhns, DB; Wechsler, HL; Zdziarski, UE | 1 |
8 other study(ies) available for glucose, (beta-d)-isomer and Symptom Cluster
Article | Year |
---|---|
Role of 5-lipoxygenase in the multiple organ failure induced by zymosan.
Topics: Animals; Arachidonate 5-Lipoxygenase; Lipid Peroxidation; Male; Mice; Mice, Knockout; Models, Animal; Multiple Organ Failure; Nitric Oxide; Peritonitis; Random Allocation; Syndrome; Zymosan | 2004 |
Polymorphonuclear leukocyte dysfunction syndrome in patients with increasing sepsis severity.
Topics: C-Reactive Protein; Calcimycin; Calcitonin; CD18 Antigens; Humans; Hydrogen Peroxide; Interleukin-6; Leukocyte Count; Middle Aged; Multiple Organ Failure; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Activation; Neutrophils; Opsonin Proteins; Phagocytosis; Protein Precursors; Sepsis; Severity of Illness Index; Shock, Septic; Syndrome; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha; Zymosan | 2006 |
Increasing cytotoxic activity and production of reactive oxygen and nitrogen intermediates by peritoneal macrophages during the development of multiple organ dysfunction syndrome in mice.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Cytotoxicity, Immunologic; Disease Models, Animal; Inflammation; Macrophage Activation; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Nitric Oxide; Phagocytosis; Superoxides; Syndrome; Zymosan | 1996 |
Two chemotactic factors, C5a and MIP-1alpha, dramatically alter the mortality from zymosan-induced multiple organ dysfunction syndrome (MODS): C5a contributes to MODS while MIP-1alpha has a protective role.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chemokine CCL3; Chemokine CCL4; Chemotactic Factors; Complement C5a; Female; Heart Diseases; Liver Diseases; Lung Diseases; Lymphatic Diseases; Macrophage Inflammatory Proteins; Male; Mice; Mice, Knockout; Multiple Organ Failure; Syndrome; Zymosan | 1996 |
Cell wall preparations from environmental yeasts: effect on alveolar macrophage function in vitro.
Topics: Agricultural Workers' Diseases; Animals; Dose-Response Relationship, Drug; Dust; Leukotriene B4; Lung; Macrophages, Alveolar; Phagocytosis; Pneumonia; Rats; Rats, Sprague-Dawley; Sheep; Superoxides; Syndrome; Tumor Necrosis Factor-alpha; Yeasts; Zymosan | 1998 |
Hypereosinophilic syndrome human eosinophil degranulation induced by soluble and particulate stimuli.
Topics: Calcimycin; Cytoplasmic Granules; Eosinophilia; Eosinophils; Humans; Microscopy, Electron; Phagocytosis; Syndrome; Zymosan | 1988 |
Aberrant phagocyte function in Shwachman syndrome.
Topics: Agranulocytosis; Chemotaxis, Leukocyte; Child; Exocrine Pancreatic Insufficiency; Humans; Luminescent Measurements; Monocytes; Neutropenia; Neutrophils; Phagocytosis; Syndrome; Zymosan | 1987 |
Increased plasma chemoattractant in Sweet's syndrome.
Topics: Adult; Aspirin; Chemotaxis, Leukocyte; Dialysis; Hot Temperature; Humans; Isotretinoin; Leukocytosis; Male; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Pentose Phosphate Pathway; Phagocytosis; Plasma; Skin Diseases; Syndrome; Tretinoin; Zymosan | 1985 |